Paradise Valley Unified School District No. 69 building. The Anti-Defamation League filed a complaint with the U.S. Department of Education about alleged civil rights violations against a Phoenix middle-schooler's faith identity by the Paradise Valley Unified School District. The 24-page complaint filed Oct. 16, argues the Paradise Valley school district was dismissive of, delayed in responding to and engaged in victim-blaming of a 14-year-old Jewish female student's month-long harassment.
Michael Clancy
Phoenix
Reporter at The Arizona Republic in Phoenix. What are folks talking about in your circles? Let me know. mike.clancy@ arizonarepublic.com
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Michael Clancy
The EU Commission market-tests commitments offered by an influenza vaccine manufacturer to address preliminary concerns of misleading disparagement of a rival’s vaccine in the immunisation sector (Sanofi)
Estimated reading time: 4 min In its ongoing investigation of Sanofi for the alleged disparagement of a rival vaccine (see, Van Bael & Bellis Life Sciences News and Insights of 29 June 2026), the European Commission (Commission) published a communication on 8 July 2026 summarising its preliminary assessment that Sanofi may have abused its dominant position (the Communication). The Commission also published commitments proposed by Sanofi (the Commitments) to seek to resolve the case.
The EU Commission opens its first formal antitrust investigation in the medical devices sector into a suspected abuse of dominance by a dental company for allegedly tying access to its clear aligners to the use of its intra-oral scanners (Align Technology
Estimated reading time: 1 min On 30 June 2026, the European Commission (the Commission) announced that it opened a formal investigation into medical device company Align Technology (Align) under Article 102 of the Treaty on the Functioning of the European Union (TFEU) and Article 54 of the European Economic Area Agreement, on suspicion that Align has engaged in abusive exclusionary conduct by tying access to its Invisalign® clear aligners, in the market for which it allegedly holds a dominant...
The UK Competition Authority and EU Commission introduce updated technology transfer block exemption frameworks
Temps de lecture estimé : 6 mn The European Commission has adopted a new competition law framework governing technology transfer agreements, while the UK has introduced a new block exemption order and is consulting on accompanying draft guidance issued by the CМА. European Union.
The EU Commission ends an investigation of a supplier of cardiovascular medical devices (Edwards Lifesciences) – Concurrences
Estimated reading time: 2 min On 16 February 2026, the European Commission (the Commission) decided to terminate its antitrust investigation into allegedly anticompetitive behaviour by Edwards Lifesciences (Edwards), based in Irvine, California, which supplies medical devices for cardiovascular applications (see, attached press release).
The Belgian Competition Authority seeks feedback on draft guidance for competition compliance in public procurement – Concurrences
Estimated reading time: 2 min On 6 January 2026, the Belgian Competition Authority (BCA) started a public consultation regarding draft guidance on the application of the competition rules to public procurement (see, attachments). The draft guidance is designed to help public procurement managers prevent anticompetitive conduct from happening and identify any such behaviour if the preventive measures fail.
The Belgian Competition Authority opens an in-depth abuse of dominance investigation in the pharmaceutical data services sector (IQVIA) – Concurrences
The Belgian Competition Authority (BCA) announced today that it would start a thorough investigation of the commercial practices of IQVIA, a company which the BCA describes as “active in the supply (…) of technological solutions and data analysis to support pharmaceutical, biotechnology, and medical device companies in the development and commercialisation of their products” (see, attached press release). IQVIA stands accused of unspecified abusive behaviour in the sector of pharmaceutical da...
The EU Commission publishes a policy paper rejecting the potential extension of legal professional privilege to in-house lawyers – Concurrences
Estimated reading time: 2 min On 10 November 2025, the European Commission (“Commission”) published a policy brief discussing the scope of legal professional privilege (“LPP”) and the possible extension of LPP to also include communications of in-house lawyers. The policy brief was published in the context of the ongoing process to update the EU competition procedural rules set out in Regulation 1/2003 (see VBB on Competition Law, Volume 2025, Nos.
The French Competition Authority fines a dominant telemedicine platform for foreclosure conduct and a killer acquisition (Doctolib) – Concurrences
Estimated reading time: 1 min In a decision which came out today (see, attached press release), the French competition authority (FCA) imposed a fine of more than EUR 4.5 million on a firm called Doctolib which is active in telemedicine. Doctolib was found to have a dominant position in two distinct markets, namely the service market for online medical appointment bookings and the technology market for remote medical consultation solutions.
The Dutch Competition Authority proposes a new framework to define “acceptable” prices for high-cost medicines – Concurrences
On 15 October 2025, the Dutch Competition Authority (Autoriteit Consument & Markt – ACM), the Dutch Healthcare Authority (Nederlandse Zorgautoriteit – NZa) and the National Health Care Institute (Zorginstituut Nederland – ZIN) jointly published a proposal outlining a new framework for determining what constitutes a “societally acceptable” price for high-cost medicines. The initiative builds on a 2021 request from the Dutch House of Representatives, which asked these three bodies to examine...
The French Competition Authority publishes a report into competition in the veterinary sector – Concurrences
On 24 October 2025, the French Competition Authority (FCA) published its opinion on the veterinary sector which ostensibly focuses on the prices of medicines for veterinary use and of veterinary healthcare but also addresses other issues such as market concentration and relationships in the supply chain (see, attached FCA press release (in French and in English) and FCA report (only in French)). The French inquiry is just one in a series of veterinary market investigations around Europe, incl...
The Swedish Competition Authority discontinues its investigation into alleged excessive pricing of an orphan medicine (Lupin / Macure) – Concurrences
Temps de lecture estimé : 3 mn On 15 October 2025, the Swedish competition authority (Konkurrensverket) announced that it would discontinue its investigation into the alleged excessive pricing of Namuscla (mexiletine), an orphan medicine approved for treatment of inherited muscle disorders (Non-Dystrophic Myotonia – NDM). Namuscla is marketed by Lupin and distributed in Sweden by Macure Pharma.
The UK Competition Authority publishes provisional findings identifying widespread problems in the veterinary services market for pets – Concurrences
Estimated reading time: 2 min The UK Competition and Markets Authority (CMA) published today its provisional findings in its probe of veterinary services for pets. Attached are (i) the CMA’s press release; (ii) a summary of the provisional decision; and (iii) a notice of provisional findings. The full text of the provisional decision is still to be published. According to the CMA, this will happen “shortly”.
The EU Commission and the United States publish a Joint Statement on framework for reciprocal fair and balanced trade covering pharmaceuticals – Concurrences
On 21 August 2025, the European Union and the United States published a Joint Statement (JS) “on a United States-European framework on an agreement on reciprocal, fair and balanced trade” (see, attachment). As the first part of its title indicates, the JS is the start of a process which the parties say will over time cover additional areas and “increase their trade and investment relationship”. Additionally, further measures, including rules of origin, still have to be negotiated. By contrast...
Eulogy 2004 1080p WEB-DL HEVC x265-RMTeam
Eulogy 2004 1080p WEB-DL HEVC x265-RMTeam [RR/NF/CU] Size: 1.5GB RMTeam x265 mkv HEVC (MAIN) / AAC (LC) HD 1920x1080 +Subtitle All releases of "Eulogy" Eulogy (2004) Genre: Comedy | Drama Directed By: Michael Clancy Cast: Ray Romano, Jesse Bradford, Hank Azaria MPAA Rate: R Country: United Kingdom, Germany, United States Original Language: English Storyline: A black comedy that follows three generations of a family, who come together for the funeral of the patriarch - unveiling a litany of...
Eulogy 2004 1080p AMZN WEB-DL DD+ 2 0 H 264-GPRS
Here We Go S03E06 Versions: 206MB 583MB 1.2GB Gangs of London S03 Pack Versions: 4.4GB 5.9GB Betrothed to My Sister's Ex S01E09 Versions: 61MB 140MB 1.4GB Digman! S02E08 Versions: 85MB 86MB 105MB 169MB 232MB 474MB 1.4GB Secrets of the Silent Witch S01E09 Versions: 57MB 129MB 1.4GB Watari-kun's ****** Is about to Collapse S01E09 Versions: 53MB 53MB 122MB 122MB 1.3GB 1.3GB The Nice Guy S01E14 Versions: 197MB 549MB 2.1GB The Nice Guy S01E13 Versions: 189MB 531MB 2GB Tougen Anki: Dark Demon of...
European Union And United States Agree On Import Tariffs For Pharmaceutical Products
VB Van Bael & Bellis More Van Bael & Bellis is a leading independent law firm based in Brussels, with a second office in Geneva dedicated to WTO matters. The firm is well known for its deep expertise in EU competition law, international trade law, EU regulatory law, as well as corporate and commercial law.
AbbVie Scores Major Win Defending its Humira® Pricing in the Netherlands Against Private Excessive Pricing Action
On 9 July 2025, the Court of First Instance of Amsterdam (the ) dismissed as inadmissible the action which the Pharmaceutical Accountability Foundation (“ ” - ) had brought against several AbbVie affiliates ( ) on account of the allegedly excessive prices which AbbVie charged for Humira® (active substance: adalimumab) in the Netherlands between 2004 and 2016 ( , attached judgment).
CLANCY: The Judicial Coup Against Donald Trump Is Real
The Trump administration is right: rogue district court judges are orchestrating a judicial coup that is intent on undermining President Donald Trump.
The Bulgaria Competition Authority begins sector inquiry of wholesale and retail markets for medicines – Concurrences
On 20 June 2025, the Bulgarian competition authority (Commission for the Protection of Competition – CPC ) announced that it would start a sector inquiry of the wholesale and retail markets for medicines (see, attached decision of 19 June 2025). The inquiry will focus on both structural aspects of the market and the conduct of specific market players. The structural analysis will target the regulatory framework, market dynamics, market concentration, entry barriers, and market participants. ...
The EU Commission and the UK Government conclude negotiations on the Competition Cooperation Agreement – Concurrences
On 19 May 2025, the EU and UK issued a joint statement announcing the successful conclusion of negotiations of a EU-UK Competition Cooperation Agreement (the “Agreement”), and on 20 May 2025 published the text of the Agreement, which remains subject to ratification. The Agreement addresses cooperation between the competition authorities of the UK and EU concerning the application of the competition laws on anticompetitive agreements, abuse of dominance, and merger control in the UK and at EU ...
The EU Commission fines a drugmaker €462.6M for manipulation of the IP system and disparagement (Teva) – Concurrences
As previously reported (VBB on Competition Law, Volume 2024, No. 10), on 31 October 2024, the European Commission (the “Commission”) imposed a €462.6 million fine on Teva for alleged anticompetitive actions to hinder competition for its blockbuster multiple sclerosis medicine Copaxone, including a divisional patent strategy and a disparagement campaign (the “Decision”). This case marks the first infringement decision by the Commission regarding these types of conduct, which were part of a bro...
The Belgian Competition Authority accuses a pharmaceutical company of implementing a strategy to hamper biosimilar market entry in the oncology market (Roche) - Concurrences
Previous article Next article Share on | Today, the Belgian Competition Authority (BCA) accused the Roche group of having implemented a strategy between 2017 and 2020 designed to delay the market entry of biosimilar rivals of its oncology medicines MabThera® (rituximab) and Herceptin® (trastuzumab) (see, attached press release).
The EU Commission publishes a report on its study of antitrust remedies – Concurrences
Previous article Next article Share on | On 20 February 2025, the European Commission published the results of a study evaluating the implementation and effectiveness of EU antitrust remedies imposed in over 100 non-cartel antitrust decisions adopted by the Commission between January 2003 and December 2022.The study is part of the broader ongoing evaluation of Regulation 1/2003.
Court of Justice of European Union Clarifies Concept of ‘Advertising of Medicinal Products’
On 27 February 2025, the Court of Justice of the European Union (CJEU) clarified the phrase ‘advertising of medicinal products’ within the meaning of Directive 2001/83/EC on the Community code relating to medicinal products for human use (Directive 2001/83/EC).
Critical Medicines Alliance Publishes Report on Shortages of Critical Medicines
On 28 February 2025, the Critical Medicines Alliance (CMA) published its Strategic Report on shortages of critical medicines (see, attachment – the Report). The CMA was established in April 2024 as a broad-based coalition of governmental authorities, businesses, industry associations, and non-governmental organisations (see, Van Bael & Belis Life Sciences News and Insights of 25 April 2024). It currently has 279 members and 7 observers.
The Court of First Instance of Rotterdam fines a pharmaceutical company over €17M for abuse of dominant position and dismisses claims of collusion against its medication (Leadiant) - Concurrences
Previous article Next article Share on | On 13 February 2025, the Court of First Instance of Rotterdam (Rechtbank Rotterdam – the Court ) largely confirmed the decision of the Dutch competition authority (Autoriteit Consument & Markt - ACM ) of 22 June 2023 to impose a fine for excessive pricing on Leadiant (see, attached judgment I and see, Van Bael & Bellis Life Sciences News & Insights, 12 July 2023).
The Netherlands - Leadiant Sees Excessive Pricing Decision Largely Confirmed By Rotterdam Court
On 13 February 2025, the Court of First Instance of Rotterdam (Rechtbank Rotterdam – the Court) largely confirmed the decision of the Dutch competition authority (Autoriteit Consument & Markt - ACM) of 22 June 2023 to impose a fine for excessive pricing on Leadiant (see, attached judgment I and see, Van Bael & Bellis Life Sciences News & Insights, 12 July 2023).
The EU Commission imposes a €462.6M fine on a pharmaceutical company for misusing the patent system and disparaging a rival's product (Teva)
European Commission Imposes Heavy Fine on Teva for Misuse of Patent System and Disparaging Rival’s Product* Today, the European Commission (the Commission) fined Teva EUR 462.6 million for abusing its dominant position to delay the market entry of rival medicines for the treatment of relapsing forms of multiple sclerosis (see, attached press release and statement). The Commission established that Teva artificially delayed competition and extended the patent protection of its product Copaxone®...
The EU Commission fines a pharmaceutical company €462.6M for abusing its dominant position to delay the market entry of rival medicines for the treatment of relapsing forms of multiple sclerosis (Teva)
European Commission Imposes Heavy Fine on Teva for Misuse of Patent System and Disparaging Rival’s Product* Today, the European Commission (the Commission) fined Teva EUR 462.6 million for abusing its dominant position to delay the market entry of rival medicines for the treatment of relapsing forms of multiple sclerosis (see, attached press release and statement). The Commission established that Teva artificially delayed competition and extended the patent protection of its product Copaxone®...
HTA Regulation - European Commission Publishes Implementing Regulation Managing Conflicts of Interest
The European Commission publishes today the third of six Regulations implementing the Regulation on Health Technology Assessment (HTA) (Regulation (EU) 2021/2282 of 15 December 2021 on health technology assessment and amending Directive 2011/24/EU) (see, Van Bael & Bellis Life Sciences News & Insights of 15 December 2021 and Van Bael & Bellis Life Sciences News & Insights of 22 December 2021) (the HTA Regulation).
Romania - Roche Fails in Attempts to Have Findings of Abusive Behaviour in relation to Oncology Medicines Overturned
The Romanian Competition Council (Consiliul Concurenţei or CC) published last week the attached press release indicating that it had prevailed in litigation with Roche over a decision which it took at the end of 2019 to fine Roche for abusive behaviour to protect part of its oncology franchise (MabThera® (rituximab) and Herceptin® (trastuzumab)) against both other sources of the reference medicines and several biosimilar versions (see, Van Bael & Bellis Life Sciences News & Insights of 23...
The Swiss Competition Authority and European Commission terminate their investigations into a pharmaceuticals company under suspicion of anticompetitive patent litigation (Novartis)
Previous article Next article Share on | The Swiss Competition Authority ( Competition Commission or Comco ) indicated today that it terminated its inquiry into patent litigation conducted by Novartis to protect Cosentyx®, a human IgG1 monoclonal antibody indicated for the treatment of several autoimmune diseases, including specific dermatological conditions (see, attached press release in four language versions).
Belgium - New Royal Decree Establishes Import Regimes for Unlicensed Medicines
The Belgian Official Journal of 30 September 2024 contains a Royal Decree of 12 September 2024 (the RD) which will make it possible to import into Belgium medicines that do not benefit from a marketing authorisation (see, attachment). The RD creates two import regimes. The first seeks to satisfy special needs (speciale behoeften/besoins spéciaux) that result from shortages during the time of critical unavailability of a given medicine.
Belgium | Royal Decree of 1 September 2024 Completes Implementation of Regulation (EU) 2019/6 on Veterinary Medicinal products
The Belgian Official Journal (Belgisch Staatsblad / Moniteur belge) published today a Royal Decree of 1 September 2024 on veterinary medicinal products (Koninklijk Besluit van 1 september 2024 betreffende diergeneesmiddelen / Arrêté royal du 1er septembre 2024 sur les médicaments vétérinaires – the RD). The RD completes the implementation of Regulation (EU) 2019/6 and of the Law of 5 May 2022 on veterinary medicinal products.
Advanz Pharma Succeeds in Obtaining Temporary Reprieve of Revocation of Conditional Marketing Authorisation for Ocaliva®
On 4 September 2024, the President of the General Court of the European Union (the General Court) temporarily suspended the Implementing Decision of 30 August 2024 (the ID) of the European Commission (the Commission) that had revoked the conditional marketing authorisation (the CMA) for Ocaliva®, a prescription medicine used to treat adults with primary biliary cholangitis (PBC), an autoimmune condition that is responsible for the gradual destruction of the bile ducts in the liver and may...
Draghi Publishes Report on Future of European Competitiveness: EU Pharmaceutical Sector Needs to Bolster Innovation and Improve Intra-EU Coordination
On 9 September 2024, former Italian Prime Minister and President of the European Central Bank Mario Draghi published a comprehensive report on the future of European competitiveness (the Report – see attachment). The Report was commissioned by European Commission President Ursula von der Leyen and follows by only a few months another expert report – authored by another former Italian Prime Minister, Enrico Letta – on enhancing the EU single market.
The EU Court of Justice overrules the Commission’s approach to reviewing below-threshold mergers in a landmark judgment (Illumina / Grail)
Previous article Next article Share on | Yesterday, the Grand Chamber of the Court of Justice of the European Union (the CJEU ) set aside the judgment in which the General Court ( GC ) had confirmed the competence of the European Commission (the Commission ) to review (and ultimately prohibit) the acquisition of Grail by Illumina and annulled the Commission’s decisions to accept to review this case following referral requests by France and other Member States (CJEU, judgment of 3 September in...
The EU Court of Justice overrules the Commission’s approach to reviewing below-threshold mergers in a landmark judgment (Illumina / Grail)
Yesterday, the Grand Chamber of the Court of Justice of the European Union (the CJEU ) set aside the judgment in which the General Court ( GC ) had confirmed the competence of the European Commission (the Commission ) to review (and ultimately prohibit) the acquisition of Grail by Illumina and annulled the Commission’s decisions to accept to review this case following referral requests by France and other Member States (CJEU, judgment of 3 September in Joined Cases C-611/22 P and C-625/22 P...
The Hellenic Competition Authority issues statement of objects against a pharmaceutical company for alleged exclusionary behaviour on the market for treatment of macular diseases (Novartis)
The Greek competition authority ( Hellenic Competition Commission or ) announced on 29 August 2024 that it issued a Statement of Objections ( ) against Switzerland-based Novartis and that firm’s Greek subsidiary on account of suspected exclusionary behaviour on the Greek market for the treatment of macular diseases (see, attached press release). The abusive conduct allegedly took place between 2009 and 2017 in two forms: First, Novartis supposedly paid physicians and healthcare inst...
The Hellenic Competition Authority issues a Statement of Objections against a pharmaceutical company for alleged exclusionary behaviour in the market for treatment of macular diseases (Novartis)
The Greek competition authority ( Hellenic Competition Commission or ) announced on 29 August 2024 that it issued a Statement of Objections ( ) against Switzerland-based Novartis and that firm’s Greek subsidiary on account of suspected exclusionary behaviour on the Greek market for the treatment of macular diseases (see, attached press release). The abusive conduct allegedly took place between 2009 and 2017 in two forms: First, Novartis supposedly paid physicians and healthcare inst...
The Hellenic Competition Authority issues a statement of objects against a pharmaceutical company for alleged exclusionary behaviour in the market for treatment of macular diseases (Novartis)
The Greek competition authority ( Hellenic Competition Commission or ) announced on 29 August 2024 that it issued a Statement of Objections ( ) against Switzerland-based Novartis and that firm’s Greek subsidiary on account of suspected exclusionary behaviour on the Greek market for the treatment of macular diseases (see, attached press release). The abusive conduct allegedly took place between 2009 and 2017 in two forms: First, Novartis supposedly paid physicians and healthcare inst...
Belgium - Committees for Borderline Products for Human and Veterinary Use Replace Mixed Committee
On 19 August 2024, the Belgian Official Journal published a Royal Decree of 16 July 2024 determining the composition, tasks and functioning of the Committee for Borderline Products for Human Use and the Committee for Borderline Products for Veterinary Use and implementing Articles 12/1 and 12/2 of the Law of 20 July 2006 on the establishment and functioning of the Federal Agency for Medicines and Health Products (FAMHP) (Koninklijk Besluit van 16 juli 2024 tot vaststelling van de...
European Commission Authorises EUR 2 Billion Aid Package in Support of Nuclear Medicine under European State Aid Rules
On 26 July 2024, the European Commission (the Commission) authorised a EUR 2 billion financing scheme by the Dutch government to support the construction and operation of a nuclear reactor and health centre in Petten, the Netherlands (see, attached Commission press release).
The Spanish Competition Authority fines an online hotel booking platform for abusing its dominant position through unfair trading conditions (Booking.com)
On 29 July 2024, the Spanish Competition Authority (“SCA”) imposed its largest ever fine (€ 413 million) on Booking.com, the leading online travel agent, for abusing its dominant position in the market for intermediary online travel agent services for hotels. In its decision, the SCA found that Booking.com committed an exploitative abuse by imposing unfair trading conditions on hotels. According to the applicable case-law (see BRT v SABAM, C-127/73), unfair trading conditions imposed by a dom...
The EU Commission authorises a €2B financing scheme by the Dutch government to support the construction and operation of a nuclear reactor and health centre (Pallas Project)
Previous article Next article Share on | On 26 July 2024, the European Commission (the Commission ) authorised a EUR 2 billion financing scheme by the Dutch government to support the construction and operation of a nuclear reactor and health centre in Petten, the Netherlands (see, attached Commission press release).
Parallel Trade - Belgian Courts Ban Rebranding of Generic Medicines as Originator Medicines
On 10 June 2024, the Brussels Court of Appeal held in two judgments in disputes pitting parallel importers (PI Pharma and Impexeco, respectively) against Novartis that parallel importers cannot validly import a generic medicinal product and repackage and rebrand it with the brand name of the pioneering substance.1 A few days earlier, on 23 May 2024, the President of the Dutch-language Brussels Enterprise Court had delivered a similar judgment in cease-and-desist proceedings initiated by...
The EU Commission accepts commitments from global pharmaceutical company to address anticompetitive disparagement agreement for iron medicine (Vifor)
Previous article Next article Share on | The European Commission (the Commission ) has ended competition proceedings against Vifor Pharma ( Vifor ) by accepting commitments which Vifor had presented to address the Commission’s concerns relating to Vifor’s possible disparagement of Monofer®, a medicine of Pharmacosmos and the closest competitor of Vifor’s intravenous iron deficiency treatment, Ferinject® (see, attached press release of today).
The EU Commission accepts commitments from a global pharmaceutical company to address the anticompetitive disparagement of a rival's intravenous iron medicine (Vifor)
The European Commission (the Commission ) has ended competition proceedings against Vifor Pharma ( Vifor ) by accepting commitments which Vifor had presented to address the Commission’s concerns relating to Vifor’s possible disparagement of Monofer®, a medicine of Pharmacosmos and the closest competitor of Vifor’s intravenous iron deficiency treatment, Ferinject® (see, attached press release of today).
Toward a Ginsparg-Wilson lattice Hamiltonian
Abstract To address quantum computation of quantities in quantum chromodynamics (QCD) for which chiral symmetry is important, it would be useful to have the Hamiltonian for a fermion satisfying the Ginsparg-Wilson (GW) equation. I work with a solution to the GW equation which is fractional linear in time derivatives. The resulting Hamiltonian is nonlocal and has ghosts, but is free of doublers and has the correct continuum limit.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Michael
Contact Michael, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack